The Barron’s write-up on GILD’s valuation is rather superficial, IMO, insofar as it doesn’t even mention the risk to GILD’s HIV franchise from TAF failure.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”